Semax: The ACTH-Derived Neuropeptide With a Favourable PCAC Vote, Three Decades of Russian Clinical Use, and No Western Regulatory Approval

Key takeaways

• Semax is a synthetic heptapeptide analogue of ACTH(4–10), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and approved in Russia since 1994 for cerebrovascular and cognitive indications.
• On 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–5, with one abstention, to recommend Semax for inclusion on the Section 503A Bulk Drug Substances List — against the recommendation of FDA career staff.
• The vote is non-binding. Full rulemaking, including a public comment period and final FDA determination, is expected to take 12–24 months before legally compounded Semax could reach licensed pharmacies.
• Semax is not authorised as a medicine by the MHRA and has not been evaluated by the EMA. In the UK, it may be supplied for research purposes under specific statutory frameworks, but therapeutic claims and direct-to-consumer supply are prohibited.
• The evidence base, though substantive by preclinical standards, relies predominantly on Russian-conducted trials and animal studies in ischaemia models; it does not meet modern Western regulatory standards for clinical efficacy.

What Semax Is

Semax is a synthetic peptide analogue of ACTH(4–10) developed to retain neurological activity without the adrenal effects of the full hormone. Its amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro — a heptapeptide in which the C-terminal Pro-Gly-Pro extension confers metabolic stability relative to native ACTH fragments. It was approved by the Russian Ministry of Health in 1994 for cerebrovascular indications and has been in clinical use in Russia for more than three decades for ischaemic stroke, cognitive decline, and optic nerve disorders.

In Russia, Semax is a registered prescription pharmaceutical and is listed on the country's List of Vital and Essential Drugs, added in 2011. Approved indications include stroke, transient ischaemic attack, cognitive disorders, optic nerve disease, and peptic ulcer. This regulatory standing does not confer equivalence with FDA approval or MHRA authorisation, and differences in product composition, clinical-trial standards, and pharmacovigilance frameworks must be considered when evaluating the Russian data.

Mechanism of Action

The primary proposed mechanism involves modulation of neurotrophin signalling. The primary mechanism driving Semax's reported neurological effects is upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), both master regulators of synaptic plasticity, neuronal survival, and cognitive function. Alongside these neurotrophic pathways, Semax is proposed to act through melanocortin receptor modulation (as an ACTH fragment), and modulation of dopaminergic and serotonergic systems.

A more recently characterised dimension of mechanism involves the hypoxia-inducible factor 1-alpha (HIF-1α) transcription factor and its downstream gene regulatory network. Molecular studies using models of cerebral ischaemia in rats showed that Semax acts on the brain transcriptome: it enhances transcription of neurotrophins and their receptors, significantly affects the expression of genes associated with immune response, suppresses activation of inflammation-associated genes, and prevents the decrease in expression of genes associated with neurotransmission.

Genome-wide transcriptional analyses published in BMC Genomics (2014) and Molecular Genetics and Genomics (2017) characterise Semax's neuroprotective profile at the gene expression level, showing modulation of immune-response and vascular-system gene expression in focal brain ischaemia models. Transcriptome and proteome analyses published in Genes (2020) and in the International Journal of Molecular Sciences (2021) confirmed Semax's protective signature following cerebral ischaemia-reperfusion in rodent models. The authors note that these are mechanistic studies, not clinical outcome data, but that they provide a molecular basis for the functional findings in the clinical programme.

At the protein level, a 2021 study published in the International Journal of Molecular Sciences found that at 24 hours after transient middle cerebral artery occlusion (tMCAO) in rats, Semax was associated with upregulation of active CREB in subcortical structures, downregulation of MMP-9 and c-Fos in adjacent cortex, and downregulation of active JNK — collectively suggesting suppression of inflammatory and cell death processes and activation of recovery mechanisms.

The Evidence Base

The clinical evidence for Semax is concentrated in Russia and comprises a relatively small number of trials evaluated under Russian regulatory standards. Some human stroke studies exist, but the overall evidence has limitations and is not equivalent to FDA approval. A clinical study has demonstrated the efficacy of Semax in the treatment of patients with ischaemic stroke; the peptide improved functional recovery and motor performance.

Specifically, administration of Semax increased BDNF plasma levels, accelerated functional recovery, and enhanced motor performance in post-stroke patients. In experimental models of cerebral ischaemia, Semax administration led to recovery of animals' ability to learn in a Morris water maze and passive-avoidance task.

Genome-wide research in rats found that Semax altered the expression of genes related to immune activity and vascular function following focal cerebral ischaemia, with effects changing over time — suggesting that Semax may influence different stages of the response to neurological injury.

Research procurement teams should note that different evidentiary standards apply: the FDA and Russian regulatory authorities use different frameworks for evaluating drug safety and efficacy, and studies conducted under Russian regulatory standards may not meet all FDA requirements for clinical trial design and reporting. US-based clinical trials are limited. The PCAC review for the US 503A Bulks List evaluated Semax specifically for the indications of cerebral ischaemia and trigeminal neuralgia, not for the nootropic and cognitive-enhancement uses for which it is most widely discussed online. Healthy-person cognitive enhancement has not been established through large, replicated, high-quality trials.

The July 2026 PCAC Vote and What Follows

At the FDA's Pharmacy Compounding Advisory Committee meeting held on 23–24 July 2026, PCAC members voted in close results to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon, and Semax for inclusion on the 503A affirmative list, while voting against the addition of emideltide. For Semax specifically, the vote was reported as 8–5 with one abstention.

FDA scientific staff had firmly opposed allowing compounding of all seven peptides under review, citing a lack of safety and efficacy data. The docket, FDA-2025-N-6895, attracted approximately 1,860 public comments and became a significant flashpoint in the broader debate over the future of peptide compounding in the United States.

The practical consequence of a favourable PCAC recommendation is limited in the near term. The PCAC vote is non-binding and will still need sign-off from the FDA. A favourable vote initiates a formal rulemaking process that must include a published proposed rule, a public comment period of 60 to 90 days, and a final FDA determination. Legal experts estimate this process takes 12 to 24 months, meaning legally compounded Semax from a licensed 503A pharmacy cannot be expected before late 2027 at the earliest, and the FDA retains the authority not to follow the committee's recommendation.

An additional structural consideration: even if the agency follows the panel's advice, compounded peptides would not be immediately legal in the US — the agency would need to issue a rule to add them to the 503A bulk compounding list, which could take a year or more.

A second PCAC meeting, scheduled before the end of February 2027, will address five further peptides: LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF.

Regulatory Status: UK and EU

Semax is not authorised as a medicine by the UK Medicines and Healthcare products Regulatory Agency (MHRA). It is not classified as a controlled substance under UK drug legislation. Under current UK frameworks, Semax may be legally supplied for research and laboratory purposes, provided regulatory compliance is maintained.

Supply for research must adhere to the Human Medicines Regulations 2012 (as amended), which permit unlicensed compound supply for research, and to Good Manufacturing Practice standards for suppliers. Critically, supply must be restricted to research institutions, universities, pharmaceutical companies, and qualified researchers with appropriate facilities and ethical approval. Therapeutic claims are prohibited.

Semax has not been evaluated or approved by the EMA, and most EU member states treat it as an unauthorised medicine. Whilst Semax holds clinical approval in Russia for stroke and cognitive indications, this does not translate to UK or EU regulatory approval. UK researchers considering clinical translation must navigate standard regulatory pathways, including the Investigational Medicinal Product Dossier process, IMP classification, and MHRA consultation, appropriate to novel therapeutic development.

For research procurement teams, the implication is straightforward: Semax procured for laboratory research in the UK must be obtained from suppliers that can demonstrate GMP-compliant manufacture, provide a complete Certificate of Analysis covering identity, purity, and impurity profiling, and label products accurately as research-use only.

Position in the Broader Peptide Landscape

Semax occupies a distinctive position among the peptides currently under active US regulatory review: it is the only compound in the July 2026 PCAC cohort with a pre-existing, multi-decade history as a registered pharmaceutical in a major national market. That history provides a more substantial clinical literature than most compounds in the cohort, but it does not resolve the fundamental question the FDA must answer — whether the available data, generated under a different regulatory system, constitutes sufficient evidence of safety and clinical utility under US standards.

The broader regulatory trajectory for all six peptides that received favourable PCAC recommendations in July 2026 — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — now runs through the same rulemaking process. Research procurement professionals tracking this landscape should not interpret the PCAC vote as a change in legal status and should monitor the FDA's Federal Register for publication of a proposed rule, which would represent the next substantive milestone.